Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 391 participants.

Also called NCT01169779

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 391 participants (enrolled count) (from the registry)
Sponsor
  • Sanofi Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01169779
Main results
  • Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double-blind, placebo-controlled, 24-week trial (GetGoal-M-Asia) Diabetes/metabolism research and reviews, 2014-11 DOI, PubMed 24639432

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
China, Hong Kong SAR China, Malaysia, Thailand (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01169779. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2011-12 (actual). Results posted on 2016-10-13.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lixisenatide in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled by Metformin
Acronym
GetGoal-M-Asia
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Lixisenatide (AVE0010)
Intervention (Drug)
Placebo
Intervention (Device)
Pen auto-injector
Intervention (Drug)
Metformin
Intervention (Drug)
Sulfonylurea
Lead sponsor
Sanofi (class: industry)

Record details

Record id
cardio:ct-nct01169779
Content hash
f3dc2b609ab9b6105c5ae82d6b057ad206caefe7e4679918f7f36f0ebb7e1ed2